Page 40 - 2019_07 resto del Mondo-web

S. Copsel et al.
References
1. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their com- mon role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32.
2. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity. 2002;17(2):167-178.
3. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007;8(2):191-197.
4. Piccirillo CA, Shevach EM. Naturally-occur- ring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripher- al tolerance. Semin Immunol. 2004;16(2):81- 88.
5. Malek TR, Bayer AL. Tolerance, not immuni- ty, crucially depends on IL-2. Nat Rev Immunol. 2004;4(9):665-674.
6. Wang HY, Lee DA, Peng G, et al. Tumor-spe- cific human CD4+ regulatory T cells and their ligands: implications for immunothera- py. Immunity. 2004;20(1):107-118.
7. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associ- ated with favorable prognosis in ovarian can- cer. Proc Natl Acad Sci U S A. 2005;102(51): 18538-18543.
8. Gao Q, Qiu SJ, Fan J, et al. Intratumoral bal- ance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586-2593.
9. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306.
10. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232(2):199-209.
11. Mlecnik B, Bindea G, Angell HK, et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity. 2016;44(3):698-711.
12. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203(7):1701-1711.
13. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human reg- ulatory and activated T cells. J Exp Med. 2006;203(7):1693-1700.
14. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune recon- stitution in HLA-haploidentical transplanta- tion. Blood. 2011;117(14):3921-3928.
15. Brunstein CG, Miller JS, McKenna DH, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity pro- file, and clinical effect. Blood. 2016;127 (8):1044-1051.
16. Tang Q, Henriksen KJ, Bi M, et al. In vitro- expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199(11):1455-1465.
17. Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 2011;118(20): 5671-5680.
18. Hippen KL, Merkel SC, Schirm DK, et al.
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83):83ra41.
19. Hippen KL, Harker-Murray P, Porter SB, et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial anti- gen-presenting cells. Blood. 2008;112(7): 2847-2857.
20. Putnam AL, Brusko TM, Lee MR, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009;58(3):652-662.
21. Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using poly- clonal regulatory T cells. Sci Transl Med. 2015;7(315):315ra189.
22. Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising ther- apy. Mol Ther Oncolytics. 2016;3:16015.
23. Campbell A, Brieva T, Raviv L, et al. Concise Review: Process Development Considerations for Cell Therapy. Stem Cells Transl Med. 2015;4(10):1155-1163.
24. Gee AP. Manufacturing genetically modified T cells for clinical trials. Cancer Gene Ther. 2015;22(2):67-71.
25. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells sup- press naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001;193(11):1295-1302.
26. Esensten JH, Muller YD, Bluestone JA, Tang Q. Regulatory T cell therapy for autoim- mune and autoinflammatory diseases: the next frontier. J Allergy Clin Immunol. 2018;142(6):1710-1718.
27. Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant. 2013;13(11):3010-3020.
28. Seay HR, Putnam AL, Cserny J, et al. Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Mol Ther Methods Clin Dev. 2017;4:178-191.
29. McKenna DH, Jr., Sumstad D, Kadidlo DM, et al. Optimization of cGMP purification and expansion of umbilical cord blood-derived T- regulatory cells in support of first-in-human clinical trials. Cytotherapy. 2017;19(2):250- 262.
30. Heinrichs J, Bastian D, Veerapathran A, et al. Regulatory T-Cell Therapy for Graft-versus- host Disease. J Immunol Res Ther. 2016;1(1):1-14.
31. Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effec- tor T cells after allogeneic stem cell trans- plantation contributes to chronic GVHD. Blood. 2016;127(5):646-657.
32. Gagliani N, Gregori S, Jofra T, et al. Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces toler- ance in a stringent mouse model of islet transplantation. PLoS One. 2011;6(12): e28434.
33. Camirand G, Wang Y, Lu Y, et al. CD45 liga- tion expands Tregs by promoting interac- tions with DCs. J Clin Invest. 2014;124(10): 4603-4613.
34. Ronchetti S, Ricci E, Petrillo MG, et al. Glucocorticoid-induced tumour necrosis fac- tor receptor-related protein: a key marker of functional regulatory T cells. J Immunol Res. 2015;2015:171520.
35. Malek TR. The biology of interleukin-2.
Annu Rev Immunol. 2008;26:453-479.
36. Yu A, Snowhite I, Vendrame F, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms sup- ports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes. 2015;64(6):2172-
2183.
37. Lentsch AB, Miller FN, Edwards MJ.
Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol Immunother. 1999;47(5):243-248.
38. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low- dose interleukin-2 in patients with metastat- ic renal cancer. J Clin Oncol. 2003;21(16): 3127-3132.
39. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med. 2010;207(9): 1871-1878.
40. Rouse M, Nagarkatti M, Nagarkatti PS. The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis. Immunobiology. 2013; 218(4):674-682.
41. Tahvildari M, Omoto M, Chen Y, et al. In Vivo Expansion of Regulatory T Cells by Low-Dose Interleukin-2 Treatment Increases Allograft Survival in Corneal Transplantation. Transplantation. 2016;100 (3):525-532.
42. Wang X, Wang W, Xu J, Le Q. Effect of rapamycin and interleukin-2 on regulatory CD4+CD25+Foxp3+ T cells in mice after allogenic corneal transplantation. Transplant Proc. 2013;45(2):528-537.
43. Pilon CB, Petillon S, Naserian S, et al. Administration of low doses of IL-2 com- bined to rapamycin promotes allogeneic skin graft survival in mice. Am J Transplant. 2014;14(12):2874-2882.
44. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of func- tional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol. 2006;36 (8):2139-2149.
45. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006;311(5769):1924- 1927.
46. Wilson MS, Pesce JT, Ramalingam TR, et al. Suppression of murine allergic airway dis- ease by IL-2:anti-IL-2 monoclonal antibody- induced regulatory T cells. J Immunol. 2008;181(10):6942-6954.
47. El Beidaq A, Link CW, Hofmann K, et al. In Vivo Expansion of Endogenous Regulatory T Cell Populations Induces Long-Term Suppression of Contact Hypersensitivity. J Immunol. 2016;197(5):1567-1576.
48. Liu R, Zhou Q, La Cava A, et al. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myas- thenia. Eur J Immunol. 2010;40(6):1577- 1589.
49. Kim MG, Koo TY, Yan JJ, et al. IL-2/anti-IL-2 complex attenuates renal ischemia-reperfu- sion injury through expansion of regulatory T cells. J Am Soc Nephrol. 2013;24(10): 1529- 1536.
50. Xiao J, Yu K, Li M, et al. The IL-2/Anti-IL-2 Complex Attenuates Cardiac Ischaemia- Reperfusion Injury Through Expansion of Regulatory T Cells. Cell Physiol Biochem. 2017;44(5):1810-1827.
51. Manirarora JN, Wei CH. Combination
1318
haematologica | 2019; 104(7)